ISIN | CH0594527720 |
---|---|
Valor Number | 59452772 |
Bloomberg Global ID | UBPAIIX SW |
Fund Name | UBS (CH) Investment Fund - Equities Switzerland ESG Passive All II I-X-acc |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
8098 Zürich, Schweiz E-Mail: ubs-am-wholesale-switzerland@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland | |
Distributor(s) |
UBS AG Basel Phone: +41 61 288 20 20 |
Asset Class | Bonds |
EFC Category | Equity Switzerland |
Distribution Policy | Accumulation |
Home Country | Switzerland |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | Das Anlageziel dieses Teilvermögens besteht hauptsächlich darin, den repräsentativen Referenzindex SPI® ESG (TR) für den schweizerischen Aktienmarkt (Bench-mark) passiv nachzubilden und eine Performance zu erzielen, welche dessen Entwicklung entspricht. |
Peculiarities |
Current Price * | 1,234.15 CHF | 20.02.2025 |
---|---|---|
Previous Price * | 1,233.14 CHF | 19.02.2025 |
52 Week High * | 1,246.20 CHF | 13.02.2025 |
52 Week Low * | 1,081.95 CHF | 16.04.2024 |
NAV * | 1,234.15 CHF | 20.02.2025 |
Issue Price * | 1,234.15 CHF | 20.02.2025 |
Redemption Price * | 1,234.15 CHF | 20.02.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 2,398,056,678 | |
Unit/Share Assets *** | 1,957,378,765 | |
Trading Information SIX |
YTD Performance | +9.91% |
31.12.2024 - 20.02.2025
31.12.2024 20.02.2025 |
---|---|---|
1 month | +6.04% |
20.01.2025 - 20.02.2025
20.01.2025 20.02.2025 |
3 months | +10.61% |
20.11.2024 - 20.02.2025
20.11.2024 20.02.2025 |
6 months | +4.33% |
20.08.2024 - 20.02.2025
20.08.2024 20.02.2025 |
1 year | +13.34% |
20.02.2024 - 20.02.2025
20.02.2024 20.02.2025 |
2 years | +17.40% |
20.02.2023 - 20.02.2025
20.02.2023 20.02.2025 |
3 years | +14.15% |
21.02.2022 - 20.02.2025
21.02.2022 20.02.2025 |
5 years | +28.02% |
11.02.2021 - 20.02.2025
11.02.2021 20.02.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Nestle SA | 12.11% | |
---|---|---|
Roche Holding AG | 11.99% | |
Novartis AG Registered Shares | 11.66% | |
UBS Group AG | 5.90% | |
Compagnie Financiere Richemont SA Class A | 5.68% | |
Zurich Insurance Group AG | 4.83% | |
ABB Ltd | 4.75% | |
Holcim Ltd | 2.97% | |
Lonza Group Ltd | 2.51% | |
Alcon Inc | 2.49% | |
Last data update | 31.01.2025 |
TER | 0.01% |
---|---|
TER date | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | |
Ongoing Charges *** | 0.01% |
SRRI ***
|
|
SRRI date *** | 31.01.2025 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |
GMOs |